Celcuity Wins FDA Approval for REVTORPYK (Gedatolisib) in HR+/HER2- Metastatic Breast Cancer Without PIK3CA Mutation

FDA Grants REVTORPYK Approval for PIK3CA Wild-Type HR+/HER2- Metastatic Breast Cancer

The regulatory green light issued by the FDA on July 14, 2026 authorizes REVTORPYK™ (gedatolisib) for adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer who do not have a PIK3CA mutation detected, and who have experienced disease progression following at least one prior line of endocrine therapy in the metastatic setting. This specific label carve-out — targeting the PIK3CA wild-type, or non-mutated, patient group — is clinically significant because this population has historically presented a therapeutic challenge. Many existing targeted therapies in this class of breast cancer have been developed around PIK3CA-mutated patients, leaving those without the mutation with comparatively limited targeted options.

The company disclosed the approval via a press release issued on the same day and also hosted a live webcast and conference call at 4:30 p.m. Central Time on July 14, 2026, to discuss the regulatory outcome and its implications. An investor presentation was furnished as part of the disclosure alongside the press release. The announcement positions Celcuity as having achieved a pivotal regulatory milestone that the company has been working toward through its development of gedatolisib, a PI3K/mTOR inhibitor that has been the central asset in the company's clinical pipeline.

Commercial Launch of REVTORPYK Anticipated in Late Q3 2026

Celcuity stated in its disclosure that it anticipates the commercial launch of REVTORPYK in late Q3 2026. This represents an accelerated path from approval to commercial availability, implying that the company has been preparing its launch infrastructure ahead of the regulatory decision. The filing did not specify the exact launch date, pricing strategy, distribution channels, or initial commercial territory, and the company did not disclose projected revenue figures, market size estimates, or sales force headcount in the materials referenced in the announcement.

Investors may be watching the commercial execution of REVTORPYK's launch closely, as the transition from a development-stage pipeline to a marketed product is typically one of the most operationally demanding phases for a biopharmaceutical company of Celcuity's size. The company did not disclose this figure in the filing regarding anticipated launch costs or the extent of pre-commercial investments already made. The timeline of late Q3 2026 suggests that the company intends to have REVTORPYK available to prescribers and patients within weeks of the FDA approval date.

Supplemental NDA for PIK3CA-Mutated Breast Cancer Planned for Q3 2026 Submission

Alongside the approval news, Celcuity disclosed plans to submit a supplemental New Drug Application to the FDA in Q3 2026. This sNDA would seek approval of REVTORPYK for a distinct but related patient population: those with HR+/HER2- locally advanced or metastatic breast cancer who carry a PIK3CA mutation and have received at least one prior line of endocrine therapy. This is a separate and potentially larger patient segment from the one covered by the current FDA approval, and the supplemental application would, if approved, significantly expand the addressable market for gedatolisib.

The company stated that the sNDA submission will be based on results from the mutant cohort of the Phase 3 VIKTORIA-1 trial, which studied gedatolisib in breast cancer patients. The filing did not provide detailed efficacy or safety data from the mutant cohort within this particular announcement, but indicated that the data were sufficient to support regulatory submission. The company referenced Slide 18 of its investor presentation (Exhibit 99.2) as incorporated by reference for additional context on this supplemental application strategy.

VIKTORIA-1 Phase 3 Trial as the Clinical Foundation for Both Indications

The Phase 3 VIKTORIA-1 trial has served as the foundational clinical study supporting both the approved indication and the planned supplemental application. The trial enrolled patients across two cohorts: one comprising patients without a PIK3CA mutation (the wild-type cohort), which formed the basis of the now-approved indication, and a separate mutant cohort that will underpin the forthcoming sNDA for PIK3CA-mutated patients. This dual-cohort design allowed Celcuity to pursue regulatory approval across both molecularly defined patient populations within a single pivotal study framework.

The disclosure noted that the company's topline clinical results are based on an ongoing analysis of efficacy and safety data, and acknowledged that such data may change following a more comprehensive review. This caveat, included in the forward-looking statements section of the announcement, is standard language for biopharmaceutical disclosures at the time of regulatory submission or approval but serves as an important reminder that clinical data interpretation is an evolving process. The company did not disclose specific response rates, progression-free survival data, or overall survival figures within the announcement itself.

Gedatolisib's Mechanism of Action in PI3K/mTOR Pathway Inhibition

Gedatolisib is described in the filing context as targeting the PI3K and mTOR signaling pathways, which are well-established drivers of tumor cell growth and survival in hormone receptor positive breast cancer. The PI3K pathway is frequently dysregulated in HR+ breast cancer, and inhibitors of this pathway have become an important area of oncology drug development. The distinction between PIK3CA-mutated and PIK3CA wild-type tumors is clinically meaningful because the mutation status can influence how tumors respond to PI3K pathway inhibitors, making the separate regulatory pursuit of each population scientifically and strategically rational.

The current approval for the PIK3CA wild-type population is particularly notable because it addresses a group of patients for whom existing PI3K-targeted therapies have not historically demonstrated sufficient benefit to receive regulatory approval in the U.S. The company's ability to demonstrate a clinically meaningful treatment effect in this patient segment, to the satisfaction of the FDA, represents a differentiating factor for REVTORPYK relative to some predecessor agents in this drug class. The filing did not include specific comparative efficacy data relative to other approved therapies in this space.

Conference Call and Investor Presentation Accompany the Approval Announcement

To coincide with the FDA approval news, Celcuity hosted a live webcast and conference call on July 14, 2026, at 4:30 p.m. Central Time. The company furnished an investor presentation as Exhibit 99.2 to the disclosure, incorporating selected slides — specifically Slide 18 — by reference into the formal filing. This level of investor engagement at the moment of regulatory approval is consistent with standard practice for commercial-stage biopharmaceutical companies seeking to communicate the significance of a product launch and regulatory milestone to the investment community.

The investor presentation and press release were both furnished as exhibits to the announcement, with the filing noting that the information provided under Regulation FD is furnished and not filed for purposes of liability under the Securities Exchange Act of 1934. This distinction is a standard legal characterization in such disclosures and does not diminish the informational content or market relevance of the materials. The company did not disclose the specific contents of the investor presentation beyond the reference to Slide 18 in relation to the sNDA strategy.

Celcuity's Corporate Background and NASDAQ Listing

Celcuity Inc. is incorporated in Delaware and headquartered at 2800 Campus Drive, Suite 140, in Minneapolis, Minnesota. The company's common stock, with a par value of $0.001 per share, trades on The Nasdaq Stock Market LLC under the ticker symbol CELC. The disclosure confirms that Celcuity is not classified as an emerging growth company under the relevant rules of the Securities Act of 1933 and the Securities Exchange Act of 1934. The company's Chief Executive Officer, Brian F. Sullivan, signed the filing on July 14, 2026.

The company has been focused on developing gedatolisib as its lead therapeutic asset, and the FDA approval of REVTORPYK represents the culmination of that development effort for the PIK3CA wild-type breast cancer indication. With a commercial launch anticipated in late Q3 2026 and a supplemental application planned for the same quarter, Celcuity is entering a period of heightened operational activity. The company did not disclose details about its cash position, commercialization partnership arrangements, or financial runway in this particular announcement.

Forward-Looking Statements and Risk Factors Disclosed by Celcuity

The announcement contained an extensive section of forward-looking statements, as required under the Private Securities Litigation Reform Act of 1995. Celcuity flagged a number of risk factors that investors should consider when evaluating the company's outlook, including unforeseen delays in clinical trials, the possibility that the FDA may not approve the planned sNDA for the PIK3CA-mutated indication, potential challenges in maintaining regulatory approvals, the development of competitive therapies, and the company's ability to access capital on favorable terms. These risks are not unique to Celcuity but are characteristic of the biopharmaceutical sector broadly.

The company also noted that forward-looking statements are subject to additional risks detailed in its Annual Report on Form 10-K for the year ended December 31, 2025, and in subsequent filings. Celcuity explicitly stated that it undertakes no obligation to revise or update the report to reflect events or circumstances arising after the filing date. Investors considering the commercial and regulatory trajectory of REVTORPYK are advised by the company not to place undue reliance on forward-looking statements, which speak only as of the date of the disclosure.

Immediate Market and Investor Implications of the REVTORPYK Approval

The FDA approval of REVTORPYK for the PIK3CA wild-type HR+/HER2- metastatic breast cancer population marks a transformational event for Celcuity as an organization. The company is now positioned to generate product revenue for the first time upon commercial launch, shifting its financial profile from one characterized entirely by research and development expenditure to one that includes commercial operations. The timing of the anticipated late Q3 2026 launch means that investors may expect initial commercialization activity to begin reflecting in the company's financial disclosures in the periods that follow.

The immediate share price impact was not clear from available public information at the time of this report. Investors may be watching the progression of the commercial launch, any updates regarding the Q3 2026 sNDA submission for the PIK3CA-mutated population, and any guidance the company may provide regarding expected commercial uptake or resource allocation for the REVTORPYK launch. The dual-indication strategy — one already approved and one pending submission — suggests that Celcuity views gedatolisib as having the potential to serve a broad segment of the HR+/HER2- metastatic breast cancer market across both molecular subtypes.